Endogenous interleukin-2 serum levels in children infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 25, Issue 5, 1997, Pages 1233-1236

  Johann Liang, Rosemary ^a   Cervia, Joseph ^a   Noel, Gary J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE SEVERITY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 0030778756     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516091     Document Type: Article

References (7)

1. Smith KA. Interleukin 2: inception, impact, and implication. Science 1988;240:1169-76.
2. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. New Engl J Med 1996;335:1350-6.
3. Berstein ZP, Porter MM, Gould M, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995;86:3287-94.
4. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type I infection. J Infect Dis 1993;167:291-8.
5. Jacobson EL, Pilaro FM, Smith KA. Rational interleukin-2 therapy for HIV-positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci 1996;93:10405-10.
6. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
7. Scott-Algara D, Vuillier F, Marasescu M, deSaint Martin J, Dighiero G. Serum levels of IL-2, IL-1 alpha, TNF-alpha, and soluble receptor of IL-2 in HlV-1-infected patients. AIDS Res Hum Retroviruses 1991;7(4):381-6.